No abstract

Lung cancer is among the most complicated cancers, with an estimated 1.6 million deaths each year for both men and women. However, the proportion of lung cancer patients in developing nations has increased from 31% to 49.9% in the last two decades. There are two main subtypes of lung cancer, small‐cell lung carcinoma and non‐small‐cell lung carcinoma (NSCLC), accounting for 15% and 85% of all lung cancer, respectively. Adenocarcinoma is the most common type of lung cancer in smokers and nonsmokers in men and women regardless of their age. Chemicals in cigarette smoke and nicotine enter our bloodstream and can then affect the entire body and finally lead to the activation of several important, pro‐survival signaling pathways. The biologically active peptide of RAAS on overstimulation enhance Ang II mediates cell proliferation, fibrosis and inflammatory effects via AT1 receptor. Very few studies highlight the diagnostic and therapeutic potential of miRNAs with the EGFR‐regulated miRNA‐21.

Objective: To study the therapeutic effect of Kanglaite injection combined with chemotherapy in the treatment of late stage non-small cell lung cancer (NSCLC), and also to observe the effect of the combination treatment on immune function. Methodology: 92 patients with advaned stage of non-small cell lung cancer who admitted to First Hospital of ZiBo city hospital from May 2017 to October 2018 were randomly divided into experimental group and control group, with 46 cases respectively. The control group was treated with chemotherapy only while the experimental group was treated with Kanglaite injection combined with chemotherapy which was the basic treatment for patients, and the total treatment effective rate, adverse reaction rate and immune index of the treatments on two groups were compared. Result: The total treatment effective rate of the experimental group was 80.43%, which was significantly higher than that of the control group, which was 63.04%. The incidence of adverse reactions in the experimental group was 36.96%, which was lower than that of the control group (78.26%). The immune indexes of the experimental group (CD3+, CD4+, IgG, IgA) were better than that of the control group, respectively. The differences between the two groups were statistically significant (P<0.05).Conclusion: During the chemotherapy of late stage or advanced non-small cell lung cancer, the addition use of Kanglaite injection has a significant effect on improving tumor control and reducing the side effects of chemotherapy, and helps to improve the immune function of patients, thus it is worth promoting.